CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.2529764

Available online at: http://www.iajps.com ***Research Article***

FOOT SYNOVIAL SARCOMA AS A SOFT TISSUE MALIGNANCY WITH A LARGER PERSPECTIVE OF TUMOUR: A CASE-CONTROL RESEARCH

[1]Dr. Hafsa Ashraf, [2]Dr. Aroosa Shahbaz, [1]Dr. Zainab Sardar

[1]Benazir Bhutto Hospital, Rawalpindi, [2]Punjab Medical College, Faisalabad.

Abstract:

The tumour in somatic cells is term as synovial sarcoma (Synovial Sarcoma). Synovial sarcoma is a malignancy in soft tissue with large perspective of tumour. Synovial sarcoma has different kinds. Monophasic biphasic and poorly differentiated are its different kinds. Monophasic biphasic and poorly differentiated are its different types. It is commonly observed with its vehemence state. It is quality of (synovial sarcoma) that it can alternate. Over 90% of (synovial sarcoma) possess this feature i-e (X: 18) (P11:2; Q11.2) (synovial sarcoma). Include chromosomal estimation, histology, immunochemical staining, and imaging. The significant modality of treatment of (synovial sarcoma) is the high beam radiation before or after surgery. Malignancy may last for five years and its restrictedly abrasive presence is indigent. Size, age and histological type of tumor are means of prediction of (synovial sarcoma). Still the position of chemotherapy is under discussion.

Keywords: *Synovial Sarcoma, Monophasic, Biphasic.*

Corresponding author:

Dr. Hafsa Ashraf,

Benazir Bhutto Hospital, Rawalpindi.

QR code

Please cite this article in press Hafsa Ashraf et al., ***Foot Synovial Sarcoma As A Soft Tissue Malignancy With A Larger Perspective Of Tumour: A Case-Control Research.,*** *Indo Am. J. P. Sci, 2019; 06(01).*

CASE REPORT:

In our outpatient department (OPD) of Jinnah Hospital, Lahore (February to June 2017), a female is introduced. The age of this female is 18 years. She is suffering from the presence of extra clump on a dorsal vertebra of the foot. She told that before 2 years, the skin of his dorsal vertebra of foot begins to change colour, and then nodule begins to form. The nodule was removed through was feeling pain and unable to lift the weight. After 1month of surgery, germination of mass was observed. A depression was a notice in mass.

Figure – I: Mass on the dorsum of left foot with oedema. Another part of the body and recent significant body weight loss



In another Centre, it was confirmed that (synovial sarcoma) is monophasic by histopathology. After one year, this mass was again removed through surgery. We operated patients for final treatment. No remarkable lost in body weight was observed. Also, patients had no other ailment in past and presence of man in any other area of the body. All other conditions of the patients were checked. No abnormality was observed. Blood pressure, heartbeat, respiratory rate and temperature were measured. The pulse was 88 beats per minute, the temperature was 38.8^0C, blood pressure was 110/80mm of hg and rate of respiration was 18cycles per minutes, Moreover, swelling, icterus, pallor and lymphadenopathy was not observed. Mass was also observed on a dorsal vertebra of the foot. In the centre size of mass was 8X8cm. The mass was not hard but soft and crumbly. The mass was painful and its surrounding temperature is elevated locally. It was attached to other composition. The skin which is present close to this mass appears like sunburn and dropsical. The closely located joint was unable to move. The cortex of 2nd and 3rd metatarsal (MT) appeared thin which is observed in an x-ray of the foot. As compared, haemoglobin was elevated and reached to 44 in 1hour. The chest and abdomen were not affected at all. Magnetic resonance imaging (MRI) was performed on foot. It illustrated a random large infiltrating mass. From the dorsal vertebra of left foot exclusively including the 2nd and 3rd MT, this large mass appeared. The mass also penetrates the pith of connected MT. The middle edge of mass is intruding the praesidium of 1st MT. But its path is not included.

Figure – II: X-rays AP and oblique view of left foot: Thinning of the cortex of 2nd and 3rd MT



The size of a man is 7.5X6X5.8cm. No conversion of chest and abdomen was noticed through a computerized tomography (CT). Spindle cell neoplasm was observed by histopathology due to which synovial sarcoma is favoured. The arrangement was made for radionuclide skeletal scintigraphy. It illustrated a lit bit uptake of radionuclide is enhanced. Display area of 2nd and 3rd MT of the left foot is included. However, the remaining bony structure was normal. Synovial sarcoma was detected in the left foot of the patient. The treatment was with forefoot impairment immunohistochemically staining was done. It indicated that CP_{34} was negative and in malignant cells, Bcl_2 and CD_{99} were positive. However, in epithelioid areas, cytokeratin was positive.

Figure – III: T_2 weighted transverse section of left foot: mass involving 2nd, 3rd and 4th MT with soft tissue involvement



DISCUSSION:

The tumour in somatic cells is term as synovial sarcoma (Synovial Sarcoma). Synovial sarcoma is a malignancy in soft tissue with large perspective of the tumor [1]. Synovial sarcoma is found in large perspective in 12% – 15% of soft tissue tumour. During 21 – 40 years of lifetime, the chance of (synovial sarcoma) is more. In soft tissue sarcoma of all adults, the presence of (synovial sarcoma) is 6% – 5% [2 – 5]. Both of the genders could be affected by (synovial sarcoma). The etiological or genetic features contributing to (synovial sarcoma). The etiological or genetic features contributing to (synovial sarcoma) are not obvious. Chance of (synovial sarcoma) in different body sites are varying. The main site from which (synovial sarcoma) originate in the lower site and its chances in the lower site are 71%. However, in upper areas, the possibility of (synovial sarcoma) is less i-e 16% whereas, 13% are from the other parts of the body. Their areas include a truck with the possibility of 13% are from the other areas which are more likely to have (synovial sarcoma). These areas include a truck with the possibility of 13% and retroperitoneal area [6]. If (synovial sarcoma) is categorized on histological basic it can be divided into three different groups. These monophasic biphasic and poorly differentiated kin. These grouping made on the basis type of cells present. In monophasic (synovial sarcoma), two types of cells are small similar to round blue cell tumour. Necrosis and chances in injuries may also be observed. Chemical change like calcification observed in patients above 30years of age. This mass has unprompted development. It eventually grows and induces pain. If people are unaware of their health hazards, this disease may be present earlier in life. During the demonstration, a metastatic disorder is observed in 18% [6]. In some situation, patient may show primary later than secondaries [9]. Different aspects that contribute for identification of (synovial sarcoma) include immune-histochemical staining, histology, chromosomal assessment and imaging. On the plain x-ray films, the chemical changes like calcification may be observed. On CT [10].

Soft-tissue tumours can be indicated and identified through imaging. However, for imaging, MRI is the main modality. The absence of calcification, hemorrhagic appearance and big size of the tumor as 10 cm are some aspects of imaging which are connected with poor prediction [11]. In (synovial sarcoma), Bcl_2 is positive. The percentage of positivity of CD_{99} 60% and that of S100 is 40% other features contributing to (synovial sarcoma) identification include epithelia CAM 5.2 and EMA. In the detection of (synovial sarcoma) very, immunohistochemically is also very helpful. In order

to identify (synovial sarcoma) from leiomyoma sarcoma, wing's tumour and malignant outlying nerve sheath tumour sheath tumour, the best and is provided by immunohistochemical stain [8]. The definite and reactive test to identify (synovial sarcoma) is a reaction (RT-PCR) and fluorescence in situ hybridization fist [8]. Alternations are also observed in (synovial sarcoma). Alternations are commonly observed between the chromosome 18 and X and it contributes to 90% of alternations in this alternation (T.18) (P11.2; Q11.2), SSX1, SSX_2 & SSX_4 are observed on chromosome X while SYT gene is observed in chromosome 18. In monophasic and poorly differentiated, as such no alternation of SYT/SSX_4 is observed. However, in the biphasic type of SS, the most usual alternation found is SYT_1/SSX_1. The distinctive alternation to synovial sarcoma is X:18. This X:18 translocation contribute in a specific identification [12 – 14].

In synovial sarcomas and potential therapeutic target, the innovation mark for detection is the expression of transducing-like enhancer 1 (TLE_1) is remarkably associated with t(X:18) [15]. The procedures employed for the treatment of synovial sarcoma remain the surgery, chemotherapy and radiotherapy. When (synovial sarcoma) is treated surgically, the tumor is incised with extensive margin. In this treatment, maximum activity is conserved. Sufficient margin of 1 to 3cm is illustrated by several studies [16]. In patients with ss with pulmonary metastases, better results can be achieved by connecting pulmonary metastasectomy with a medical speciality, if research is completed [17]. If the size of the tumor is > 5cm, then for this patient, adjuvant radiation therapy is used [18]. In the radiation field, the size of the tumor is 2 to 3cm [19]. The supervision of adjuvant radiation therapy can be done in several ways. These include intensity modulated radiation therapy (1'MRT) brachytherapy and external beam therapy (neoadjuvant or adjuvant). Tumour can be initiated either before or after surgery. In patients with greater perspective of sarcomas, like synovial sarcoma, radiation technique has been evident to enhancing the rate of control of (synovial sarcoma). Any type of radiation can be used. Either of radiation can be used. Either of the types is effective [24]. The used of other assistance based on neoadjuvant and adjuvant chemotherapy is under discussion it is due to their noxious nature, their noxious nature, their use is limited [25].

Other aspects that can affect the prediction of (synovial sarcoma) include the use of radiotherapy, histology, age and size. Through the maintenance of (RT) and surgery, synovial sarcoma can sufficiently be managed at the prime area. As a result of this disease, the rate of death has been high and distant metastasis is also establishing at higher rates [28]. As compare to biphasic (synovial sarcoma) has the more predicting capacity. The patients who died after 5 years of this disease are 21%. These patients were having primary extremity sarcoma. The patients who will die within 5years of this disease are 9%. These patients lack metastasis by 5years. Those patients have chances of disease for next 5years and distinctive death rate who are having positive microscopic margin. These patients need guidance for the longer duration [4].

REFERENCES:

1. Blakely ML, Spurbeck WW, Pappo AS, Pratt CB, Rodriguez – Galindo C, Santana VM, et al. The impact of margin of resection on outcome in pediatric Non-rhabdomyosarcoma soft tissue sarcoma. Commentary. Journal of pediatric surgery. 1999; 34 (5): 672-5.
2. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft – tissue sarcoma of the limbs: a randomised trial. The Lancet. 2002; 359 (9325): 2235-41.
3. Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer. 2009; 115 (13): 2988-98.
4. Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumours of the extremity. Journal of Clinical Oncology. 2000; 18 (10): 2087-94.
5. Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. Journal of Clinical Oncology. 2000; 18 (22): 3794-803.
6. Trassard M, Le Doussal V, Hacène K, Terrier P, Ranchère D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. Journal of Clinical Oncology. 2001; 19 (2): 525-34.
7. Guadagnolo BA, E-mail: Aguadagn@mdanderson.org, Zagars GK, Ballo MT, Patel SR, Lewis VO, Pisters PWT, et al. Long-Term Outcomes for Synovial Sarcoma Treated with Conservation Surgery and Radiotherapy. Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 69; Journal Issue: 4; Other Information:

DOI.101016/jijrobp200704056; PII: S0360-3016(07)008139; Copyright (c) 2007 Elsevier Science BV, Amsterdam, Netherlands, all rights reserved; Country of input:
8. Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, et al. Synovial sarcoma is a stem cell malignancy. Stem Cells. 2010; 28 (7): 1119-31.
9. Fletcher CD, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. Vol. 5 of World Health Organization classification of tumours. Lyon, France: IARC Press; 2002.
10. Eilber FC, Dry SM. Diagnosis and management of synovial sarcoma. Journal of surgical oncology. 2008; 97 (4): 314-20.
11. Bekarev M, Elsinger EC, Villanueva-Siles E, Borzykowski RM, Geller DS. Synovial Sarcoma of the Foot. The Journal of Foot and Ankle Surgery. 2013.
12. Nakanishi H, Araki N, Sawai Y, Kudawara I, Mano M, Ishiguro S, et al. Cystic synovial sarcomas: imaging features with clinical and histopathologic correlation. Skeletal radiology. 2003; 32 (12): 701-7.
13. O'SULLIVAN P, Harris A, Munk P. Radiological features of synovial cell sarcoma. British Journal of Radiology. 2008; 81 (964): 346-56.
14. Hiraga H, Nojima T, Abe S, Sawa H, Yamashiro K, Yamawaki S, et al. Diagnosis of synovial sarcoma with the reverse transcriptase – polymerase chain reaction: analyses of 84 soft tissue and bone tumours. Diagnostic Molecular Pathology. 1998; 7 (2): 102-10.
15. Willeke F, Mechtersheimer G, Schwarzbach M, Weitz J, Zimmer D, Lehnert T, et al. Detection of SYT– SSX1/2 fusion transcripts by reverse transcriptase– polymerase chain reaction (RT–PCR) is a valuable diagnostic tool in synovial sarcoma. European Journal of Cancer. 1998; 34 (13): 2087-93.
16. Poteat HT, Corson JM, Fletcher JA. Detection of chromosome 18 rearrangement in synovial sarcoma by fluorescence in situ hybridization. Cancer genetics and cytogenetics. 1995; 84 (1): 76-81.
17. Knosel T, Heretsch S, Altendorf-Hofmann A, Richter P, Katenkamp K, Katenkamp D, et al. TLE_1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer. 2010; 46 (6): 1170-6.
18. Andrassy RJ, Okcu MF, Despa S, Raney RB. Synovial sarcoma in children: surgical lessons from a single institution and review of the literature. Journal of the American College of Surgeons. 2001; 192 (3): 305-13.
19. Stanelle EJ, Christison-Lagay ER, Healey JH, Singer S, Meyers PA, La Quaglia MP. Pediatric and Adolescent Synovial Sarcoma: Multivariate Analysis of Prognostic Factors and Survival Outcomes. Annals of surgical oncology. 2013; 20 (1): 73-9.
20. Barham P, Dragovic B, Fraser K, Hand S, Harris T, Ho A, et al. Xen and the art of virtualization. ACM SIGOPS Operating Systems Review. 2003; 37 (5): 164-77. Blakely ML, Spurbeck WW, Pappo AS, Pratt CB, Rodriguez – Galindo C, Santana VM, et al. The impact of margin of resection on outcome in pediatric Non-rhabdomyosarcoma soft tissue sarcoma. Commentary. Journal of pediatric surgery. 1999; 34 (5): 672-5.
21. Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Annals of surgery. 1994; 219 (2): 165.
22. Pisters P, Leung D, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. Journal of Clinical Oncology. 1996; 14 (5):1679-89.
23. Lewis JJ, Leung D, Casper ES, Woodruff J, Hajdu SI, Brennan MF. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Archives of Surgery. 1999; 134 (2): 190.
24. Korea JB, Lewis JJ, Brennan MF. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Annals of surgical oncology. 2003; 10 (4): 432-40.
25. Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, et al. Synovial sarcoma. Cancer. 2009; 115 (13): 2988-98.